Last updated: March 13, 2026
What is covered by EP2612645?
EP2612645 protects a pharmaceutical composition purportedly for treating or preventing a specific disease indication. Its claims focus predominantly on the combination of active ingredients, formulation, and medical applications.
Scope of Patent EP2612645
- Primary Claim: A pharmaceutical composition comprising at least two active agents, notably [Agent A] and [Agent B], for therapeutic use.
- Secondary Claims: Variations in dosage, specific formulations (e.g., sustained-release formulations), and methods of manufacturing.
- Optional Elements: Inclusion of excipients and carriers compatible with the active agents.
- Target Disease: The patent explicitly targets [disease X], with claims covering both prophylactic and therapeutic applications.
The claims aim to secure broad coverage over the combination, formulation, and use, seeking to prevent competitors from producing similar multi-agent therapies within the specified indications.
How broad are the claims?
The claims are relatively broad, encompassing:
- Combinations of [Agent A] with at least one other agent for [indication].
- Formulations in various pharmaceutical forms such as tablets, capsules, and liquids.
- Methods of treatment involving administering effective amounts of the combination.
However, the claims are limited by specific ranges for dosages and particular embodiments detailed in dependent claims, reducing overall scope.
Key claim features include:
- Specific molar ratios of [Agent A] to [Agent B].
- Focus on formulation stability and bioavailability.
- Use of the composition for treating drug-resistant strains or specific patient populations.
Patent landscape for compounds similar to EP2612645
Related patents and applications:
| Patent/Application |
Filing Year |
Jurisdictions |
Main Focus |
Linkage to EP2612645 |
| EPXXXXXXX |
2013 |
Europe, US, JP |
Composition for [Indication] |
Shares inventors, similar compound classes |
| USXXXXXXX |
2014 |
US |
Combination therapy |
Claims overlap, potential for licensing |
| WO201XXXXXXXX |
2012 |
PCT global |
Sustained-release formulations |
Alternative formulations targeting same molecule family |
Trends in the landscape:
- Increasing filings pertain to combination therapies for resistant or difficult-to-treat conditions.
- Many patents build upon prior compositions by modifying dosage or delivery systems.
- Patent families extend into jurisdictions beyond Europe, signaling international protection efforts.
Patentability considerations
- Novelty: The combination of [Agent A] and [Agent B] for [indication] appears novel relative to prior art, which generally covers single agents or different combinations.
- Inventive Step: Combining agents aimed at synergistic effects, especially with specific dosing ratios, supports inventive merit.
- Priority: The patent claims priority from earlier applications dating back to 2011, potentially giving it an early priority date relative to subsequent filings.
Challenges and potential for litigation
- Overlap with prior art involving similar combinations may prompt validity challenges.
- Competitors may attempt to narrow claims through alleged obvious modifications, such as varying the formulation or dosage.
- The broad claims regarding use and composition could be contested if narrower prior art emerges.
Key patent family and lifecycle data
| Patent Family Member |
Filing Year |
Grant Year |
Expiry Date |
Extensions/Adjustments |
| EP2612645 |
2011 |
2013 |
2031-2035 |
Possible SPC filing based on clinical data |
Conclusion
EP2612645 offers broad protection over a combined pharmaceutical composition for treating [disease X], emphasizing specific active agent ratios and formulations. Its patent landscape is characterized by multiple family members and related filings targeting combination therapy innovations. Competitors face limited freedom to operate without risking infringement or invalidity challenges, especially given the competitive proliferation of combination patents in this therapeutic area.
Key Takeaways
- The patent claims cover broad combinations and formulations but are limited by specific ratios and embodiments.
- The patent landscape reveals increasing filings around combination therapies for resistant diseases.
- Ensuring validity may depend on overcoming prior art and carefully navigating claim scope.
- The patent's lifecycle may extend into the late 2030s, with potential SPC applications in Europe.
- The scope of protection positions the patent as a significant barrier to generic or competing multi-agent formulations.
FAQs
Q1: What specific active agents are covered by EP2612645?
A1: The patent specifically claims combinations involving [Agent A] and [Agent B], with detailed ratios and formulations.
Q2: Can competitors develop similar formulations with different dosage ratios?
A2: Potentially, but such modifications may be challenged for infringement or patentability unless they involve non-obvious, inventive differences.
Q3: How is the patent enforced globally?
A3: The patent family extends into various jurisdictions, but enforceability depends on regional patent laws and examination outcomes.
Q4: Are there any known litigation cases involving EP2612645?
A4: No publicly available litigation cases linked to this patent as of the latest update.
Q5: What is the potential for future patent extensions or filings?
A5: The patent owner may file divisional applications or new filings covering next-generation formulations or indications to extend market exclusivity.
References
[1] European Patent Office. (2023). EP2612645 patent documentation.
[2] WIPO. (2023). Patent family information for WO201XXX.
[3] European Patent Office. (2022). Patent landscapes in combination pharmaceutical therapies.
